LSPedia and Pharma Logistics Announce Strategic Partnership to Revolutionize Pharmaceutical Reverse Logistics and Supply Chain Visibility

Press Statements

AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer

3rd May 2018

AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in...

BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

by Content Team

6th April 2018

ERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, announced the dosing of the...

Prothena Announces Global Neuroscience R&D Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

by Content Team

23rd March 2018

Prothena Corporation plc , a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in...

Roche’s TECENTRIQ plus chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer: Phase III IMpower131 study

by Content Team

23rd March 2018

Roche announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the...

Tasigna drug to treat children with rare form of leukemia receives FDA approval: Novartis

by Content Team

23rd March 2018

Novartis announced that the US FDA expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric...

GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus

by Content Team

23rd March 2018

GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus

GSK announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with...

Praluent extensively reduces risk of cardiovascular events in high-risk patients, and was associated with lower death rate

by Content Team

23rd March 2018

Praluent extensively reduces risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) significantly reduced the...